Financhill
Sell
27

OLYMY Quote, Financials, Valuation and Earnings

Last price:
$15.06
Seasonality move :
0.19%
Day range:
$14.65 - $15.08
52-week range:
$13.13 - $19.69
Dividend yield:
0.77%
P/E ratio:
66.14x
P/S ratio:
2.73x
P/B ratio:
3.47x
Volume:
39.7K
Avg. volume:
97.8K
1-year change:
2.73%
Market cap:
$17.1B
Revenue:
$6.5B
EPS (TTM):
$0.23

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
OLYMY
Olympus
-- -- -- -- --
AMGXF
AnGes
-- -- -- -- --
HLOSF
Healios KK
-- -- -- -- --
PPTDF
PeptiDream
-- -- -- -- --
SOLTF
Nxera Pharma
-- -- -- -- --
TAK
Takeda Pharmaceutical
$7.2B -- 0.1% -- $16.03
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
OLYMY
Olympus
$15.04 -- $17.1B 66.14x $0.12 0.77% 2.73x
AMGXF
AnGes
$0.36 -- $86.6M -- $0.00 0% 22.98x
HLOSF
Healios KK
$1.35 -- $121.7M -- $0.00 0% 32.00x
PPTDF
PeptiDream
$17.15 -- $2.2B 20.38x $0.00 0% 7.14x
SOLTF
Nxera Pharma
$6.16 -- $553.6M -- $0.00 0% 2.79x
TAK
Takeda Pharmaceutical
$13.17 $16.03 $41.8B 21.79x $0.33 4.7% 1.39x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
OLYMY
Olympus
25.88% 0.298 7.91% 1.06x
AMGXF
AnGes
-- 2.635 -- 1.10x
HLOSF
Healios KK
65.07% -0.707 34.39% 1.33x
PPTDF
PeptiDream
25.75% -2.667 6.45% 3.28x
SOLTF
Nxera Pharma
48.92% 1.984 55.24% 3.73x
TAK
Takeda Pharmaceutical
42.19% 0.312 78.44% 0.68x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
OLYMY
Olympus
$1.1B $288.8M 3.21% 4.7% 18.33% $243.3M
AMGXF
AnGes
$259.5K -$13M -37.32% -22.74% -1559.14% --
HLOSF
Healios KK
$2.8M -$1.8M -55.94% -137.21% -24.5% -$4.8M
PPTDF
PeptiDream
$17.4M -$854.5K 24.02% 34.66% -1.5% $173.8M
SOLTF
Nxera Pharma
$48.9M $5.4M -2.75% -5.58% 11.44% $10.3M
TAK
Takeda Pharmaceutical
$5.3B $1.8B 2.37% 4.01% 15.97% $1.3B

Olympus vs. Competitors

  • Which has Higher Returns OLYMY or AMGXF?

    AnGes has a net margin of 14.38% compared to Olympus's net margin of -2947.39%. Olympus's return on equity of 4.7% beat AnGes's return on equity of -22.74%.

    Company Gross Margin Earnings Per Share Invested Capital
    OLYMY
    Olympus
    69.71% $0.20 $6.6B
    AMGXF
    AnGes
    31.07% -$0.11 $158.3M
  • What do Analysts Say About OLYMY or AMGXF?

    Olympus has a consensus price target of --, signalling downside risk potential of --. On the other hand AnGes has an analysts' consensus of -- which suggests that it could fall by --. Given that Olympus has higher upside potential than AnGes, analysts believe Olympus is more attractive than AnGes.

    Company Buy Ratings Hold Ratings Sell Ratings
    OLYMY
    Olympus
    0 0 0
    AMGXF
    AnGes
    0 0 0
  • Is OLYMY or AMGXF More Risky?

    Olympus has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison AnGes has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock OLYMY or AMGXF?

    Olympus has a quarterly dividend of $0.12 per share corresponding to a yield of 0.77%. AnGes offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Olympus pays 8.27% of its earnings as a dividend. AnGes pays out -- of its earnings as a dividend. Olympus's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios OLYMY or AMGXF?

    Olympus quarterly revenues are $1.6B, which are larger than AnGes quarterly revenues of $835.2K. Olympus's net income of $231.6M is higher than AnGes's net income of -$24.6M. Notably, Olympus's price-to-earnings ratio is 66.14x while AnGes's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Olympus is 2.73x versus 22.98x for AnGes. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    OLYMY
    Olympus
    2.73x 66.14x $1.6B $231.6M
    AMGXF
    AnGes
    22.98x -- $835.2K -$24.6M
  • Which has Higher Returns OLYMY or HLOSF?

    Healios KK has a net margin of 14.38% compared to Olympus's net margin of -107.23%. Olympus's return on equity of 4.7% beat Healios KK's return on equity of -137.21%.

    Company Gross Margin Earnings Per Share Invested Capital
    OLYMY
    Olympus
    69.71% $0.20 $6.6B
    HLOSF
    Healios KK
    86.35% -$0.04 $57.8M
  • What do Analysts Say About OLYMY or HLOSF?

    Olympus has a consensus price target of --, signalling downside risk potential of --. On the other hand Healios KK has an analysts' consensus of -- which suggests that it could fall by --. Given that Olympus has higher upside potential than Healios KK, analysts believe Olympus is more attractive than Healios KK.

    Company Buy Ratings Hold Ratings Sell Ratings
    OLYMY
    Olympus
    0 0 0
    HLOSF
    Healios KK
    0 0 0
  • Is OLYMY or HLOSF More Risky?

    Olympus has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Healios KK has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock OLYMY or HLOSF?

    Olympus has a quarterly dividend of $0.12 per share corresponding to a yield of 0.77%. Healios KK offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Olympus pays 8.27% of its earnings as a dividend. Healios KK pays out -- of its earnings as a dividend. Olympus's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios OLYMY or HLOSF?

    Olympus quarterly revenues are $1.6B, which are larger than Healios KK quarterly revenues of $3.2M. Olympus's net income of $231.6M is higher than Healios KK's net income of -$3.4M. Notably, Olympus's price-to-earnings ratio is 66.14x while Healios KK's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Olympus is 2.73x versus 32.00x for Healios KK. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    OLYMY
    Olympus
    2.73x 66.14x $1.6B $231.6M
    HLOSF
    Healios KK
    32.00x -- $3.2M -$3.4M
  • Which has Higher Returns OLYMY or PPTDF?

    PeptiDream has a net margin of 14.38% compared to Olympus's net margin of -5.57%. Olympus's return on equity of 4.7% beat PeptiDream's return on equity of 34.66%.

    Company Gross Margin Earnings Per Share Invested Capital
    OLYMY
    Olympus
    69.71% $0.20 $6.6B
    PPTDF
    PeptiDream
    47.13% -$0.02 $551.4M
  • What do Analysts Say About OLYMY or PPTDF?

    Olympus has a consensus price target of --, signalling downside risk potential of --. On the other hand PeptiDream has an analysts' consensus of -- which suggests that it could fall by --. Given that Olympus has higher upside potential than PeptiDream, analysts believe Olympus is more attractive than PeptiDream.

    Company Buy Ratings Hold Ratings Sell Ratings
    OLYMY
    Olympus
    0 0 0
    PPTDF
    PeptiDream
    0 0 0
  • Is OLYMY or PPTDF More Risky?

    Olympus has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison PeptiDream has a beta of 0.826, suggesting its less volatile than the S&P 500 by 17.389%.

  • Which is a Better Dividend Stock OLYMY or PPTDF?

    Olympus has a quarterly dividend of $0.12 per share corresponding to a yield of 0.77%. PeptiDream offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Olympus pays 8.27% of its earnings as a dividend. PeptiDream pays out -- of its earnings as a dividend. Olympus's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios OLYMY or PPTDF?

    Olympus quarterly revenues are $1.6B, which are larger than PeptiDream quarterly revenues of $36.8M. Olympus's net income of $231.6M is higher than PeptiDream's net income of -$2.1M. Notably, Olympus's price-to-earnings ratio is 66.14x while PeptiDream's PE ratio is 20.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Olympus is 2.73x versus 7.14x for PeptiDream. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    OLYMY
    Olympus
    2.73x 66.14x $1.6B $231.6M
    PPTDF
    PeptiDream
    7.14x 20.38x $36.8M -$2.1M
  • Which has Higher Returns OLYMY or SOLTF?

    Nxera Pharma has a net margin of 14.38% compared to Olympus's net margin of 12.96%. Olympus's return on equity of 4.7% beat Nxera Pharma's return on equity of -5.58%.

    Company Gross Margin Earnings Per Share Invested Capital
    OLYMY
    Olympus
    69.71% $0.20 $6.6B
    SOLTF
    Nxera Pharma
    78.44% $0.09 $928.9M
  • What do Analysts Say About OLYMY or SOLTF?

    Olympus has a consensus price target of --, signalling downside risk potential of --. On the other hand Nxera Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that Olympus has higher upside potential than Nxera Pharma, analysts believe Olympus is more attractive than Nxera Pharma.

    Company Buy Ratings Hold Ratings Sell Ratings
    OLYMY
    Olympus
    0 0 0
    SOLTF
    Nxera Pharma
    0 0 0
  • Is OLYMY or SOLTF More Risky?

    Olympus has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Nxera Pharma has a beta of 0.337, suggesting its less volatile than the S&P 500 by 66.345%.

  • Which is a Better Dividend Stock OLYMY or SOLTF?

    Olympus has a quarterly dividend of $0.12 per share corresponding to a yield of 0.77%. Nxera Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Olympus pays 8.27% of its earnings as a dividend. Nxera Pharma pays out -- of its earnings as a dividend. Olympus's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios OLYMY or SOLTF?

    Olympus quarterly revenues are $1.6B, which are larger than Nxera Pharma quarterly revenues of $62.4M. Olympus's net income of $231.6M is higher than Nxera Pharma's net income of $8.1M. Notably, Olympus's price-to-earnings ratio is 66.14x while Nxera Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Olympus is 2.73x versus 2.79x for Nxera Pharma. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    OLYMY
    Olympus
    2.73x 66.14x $1.6B $231.6M
    SOLTF
    Nxera Pharma
    2.79x -- $62.4M $8.1M
  • Which has Higher Returns OLYMY or TAK?

    Takeda Pharmaceutical has a net margin of 14.38% compared to Olympus's net margin of 7.83%. Olympus's return on equity of 4.7% beat Takeda Pharmaceutical's return on equity of 4.01%.

    Company Gross Margin Earnings Per Share Invested Capital
    OLYMY
    Olympus
    69.71% $0.20 $6.6B
    TAK
    Takeda Pharmaceutical
    66.47% $0.19 $83.8B
  • What do Analysts Say About OLYMY or TAK?

    Olympus has a consensus price target of --, signalling downside risk potential of --. On the other hand Takeda Pharmaceutical has an analysts' consensus of $16.03 which suggests that it could grow by 20.8%. Given that Takeda Pharmaceutical has higher upside potential than Olympus, analysts believe Takeda Pharmaceutical is more attractive than Olympus.

    Company Buy Ratings Hold Ratings Sell Ratings
    OLYMY
    Olympus
    0 0 0
    TAK
    Takeda Pharmaceutical
    3 1 0
  • Is OLYMY or TAK More Risky?

    Olympus has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Takeda Pharmaceutical has a beta of 0.498, suggesting its less volatile than the S&P 500 by 50.209%.

  • Which is a Better Dividend Stock OLYMY or TAK?

    Olympus has a quarterly dividend of $0.12 per share corresponding to a yield of 0.77%. Takeda Pharmaceutical offers a yield of 4.7% to investors and pays a quarterly dividend of $0.33 per share. Olympus pays 8.27% of its earnings as a dividend. Takeda Pharmaceutical pays out 199.34% of its earnings as a dividend. Olympus's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Takeda Pharmaceutical's is not.

  • Which has Better Financial Ratios OLYMY or TAK?

    Olympus quarterly revenues are $1.6B, which are smaller than Takeda Pharmaceutical quarterly revenues of $7.9B. Olympus's net income of $231.6M is lower than Takeda Pharmaceutical's net income of $619.7M. Notably, Olympus's price-to-earnings ratio is 66.14x while Takeda Pharmaceutical's PE ratio is 21.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Olympus is 2.73x versus 1.39x for Takeda Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    OLYMY
    Olympus
    2.73x 66.14x $1.6B $231.6M
    TAK
    Takeda Pharmaceutical
    1.39x 21.79x $7.9B $619.7M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is The Santa Claus Rally The Gift That Keeps Giving?
Is The Santa Claus Rally The Gift That Keeps Giving?

Remember the horror of 2008 when the Great Recession hit…

Is Alphabet an Undervalued Growth Stock to Buy?
Is Alphabet an Undervalued Growth Stock to Buy?

Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…

Is Tesla Going to Buy Uber?
Is Tesla Going to Buy Uber?

Tesla has always been in the habit of making large,…

Stock Ideas

Buy
65
Is AAPL Stock a Buy?

Market Cap: $3.9T
P/E Ratio: 42x

Buy
57
Is NVDA Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 118x

Buy
58
Is MSFT Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 37x

Alerts

Buy
87
PSIX alert for Dec 25

Power Solutions International [PSIX] is up 27.42% over the past day.

Buy
65
TSLL alert for Dec 25

Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.

Buy
75
SMLR alert for Dec 25

Semler Scientific [SMLR] is up 15.37% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock